0
0
Migraines, a disabling neurological condition that affects more than 1 billion people worldwide, may one day have an unexpected new treatment option: a drug originally designed for diabetes and weight loss. A new pilot study from Italy suggests that liraglutide — a medication in the same drug class as the blockbuster diabetes drug Ozempic — could reduce migraine frequency in people with obesity. However, experts caution that much more research is needed before the medication could be considered a reliable treatment for migraine.
The Study: A Small Step Toward a Big Question
The study, led by Dr. Simone Braca and published in Headache: The Journal of Head and Face Pain (September 2025), followed 31 adults with both chronic migraines and obesity. Participants, the majority of whom were women, were given liraglutide for 12 weeks while recording their headaches in daily diaries.
At the end of the trial, the results were striking:
-
Average migraine days per month dropped from 20 to 11.
-
Fifteen participants (about 48%) reported a 50% reduction in frequency.
-
Seven participants (22%) achieved a 75% reduction.
-
One person (3%) reported complete relief.
Mild gastrointestinal side effects — including nausea and constipation, both well-documented with GLP-1 medications — occurred but did not interfere with the study.
“The early findings are encouraging because patients with treatment-resistant migraines often have very few options,” said Dr. Braca in a press release.
Why Liraglutide? The Science Behind the Idea
Liraglutide belongs to a class of medications called GLP-1 receptor agonists. These drugs mimic a natural hormone involved in regulating blood sugar, appetite, and weight. They are widely prescribed under brand names such as Victoza (for diabetes) and Saxenda (for weight management). More recently, semaglutide (sold as Ozempic and Wegovy) has gained global attention for its powerful effects on weight loss and metabolic health.
Since excess weight is a known risk factor for both migraine onset and severity, one explanation for liraglutide’s benefit might have been weight reduction. But participants in this study had almost no changes in body mass index (BMI), shifting only from 34.0 to 33.9 on average. This suggests that the drug’s effect on migraine may work through a different mechanism.
One leading hypothesis is that liraglutide could help lower intracranial pressure (ICP), the pressure inside the skull. Elevated ICP has been associated with migraines, though this relationship remains under investigation. However, the study did not measure ICP directly, leaving that question unanswered.
Expert Perspectives: Hopeful, But Far from Conclusive
Migraine specialists not involved in the research voiced cautious optimism.
“This pilot trial raises an exciting possibility, but we must be careful not to overinterpret early results,” said Dr. Elizabeth Loder, professor of neurology at Harvard Medical School and former president of the American Headache Society. “The lack of a control group and the very small study size limit our ability to say whether liraglutide truly caused the improvements or whether placebo and self-reporting biases played a role.”
Similarly, Dr. Andreas Kirsling, a researcher in neuropharmacology at the University of Copenhagen, noted that GLP-1 drugs are already under investigation for other neurological conditions, including Alzheimer’s and Parkinson’s disease. “That broader body of work makes this finding intriguing,” he said. “But migraine is a highly complex disorder, and what works in one population may not generalize to others.”
Migraines: A Major Public Health Burden
Migraines affect around 15% of the global population, according to the World Health Organization. Women are disproportionately affected, experiencing migraines up to three times more frequently than men. For many, the condition goes beyond simply having headaches — it includes disabling symptoms such as sensitivity to light and sound, nausea, and cognitive impairment.
Current treatments include preventive medications such as beta blockers, antiepileptic drugs, and the newer class of calcitonin gene-related peptide (CGRP) inhibitors. While these therapies help many, they often come with side effects or prove ineffective in some patients.
“This is why any new avenue of treatment sparks so much attention,” said Dr. Loder. “Patients are desperate for relief.”
Limitations and Next Steps
Despite the promising results, multiple limitations temper enthusiasm:
-
Small sample size: Only 31 patients completed the study.
-
No control group: Without a group of patients receiving placebo, it is difficult to determine if the improvements were truly drug-related.
-
Short duration: Twelve weeks offers only a snapshot of benefits; longer-term safety and effectiveness remain unknown.
-
Missing measures: The study did not directly assess intracranial pressure, a potential mechanism of action.
The researchers emphasize that larger randomized controlled trials, ideally with diverse populations and longer durations, are needed before liraglutide or similar medications could be recommended for migraine treatment.
What This Means for Patients
For now, doctors caution against assuming liraglutide or other GLP-1 drugs are a solution to migraines. These medications are expensive, come with side effects, and are currently approved only for diabetes or weight management.
Nevertheless, the findings add to a growing body of evidence that GLP-1 receptor agonists might have neurological benefits beyond metabolic health. If confirmed in future trials, this could potentially expand therapeutic options for patients who struggle with chronic migraines.
“Patients reading about this study should not try to obtain liraglutide off-label for migraines just yet,” said Dr. Loder. “What we need are larger, rigorous trials to know if this approach is truly safe, effective, and sustainable.”
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Braca S, et al. “Liraglutide treatment in patients with chronic migraine and obesity: A 12-week open-label pilot study.” Headache: The Journal of Head and Face Pain. September 2025.
